Somatic mutations show no clear association with red blood cell or human leukocyte antigen alloimmunization in de novo or therapy-related myelodysplastic syndrome.

ABSTRACT:

Background

Myelodysplastic syndrome (MDS) is a marrow failure disease. As patients often require chronic transfusion, many develop red blood cell (RBC) alloimmunization or immune-mediated platelet refractoriness. MDS represents a spectrum of diseases with specific categorizations and genetic abnormalities, and we set out to determine if these characteristics predispose patients to antibody formation.

Study design and methods

A natural language search identified MDS patients with pre-transfusion testing from 2015 to 2020. Marrow reports, cytogenetic results, and next-generation sequencing panels were gathered. Transfusion history and testing were collected from the laboratory information system.

Results

The group consisted of 226 biopsy-proven MDS patients. The prevale

SUBMITTER: Adkins BD 

PROVIDER: S-EPMC10866154 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature